Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership Establishing World’s First and Largest Database of Medical Cannabis Effects on Women

International Study Monitoring Real-time Cannabis Treatment for the Symptoms of Endometriosis Will Leverage Strainprint’s Comprehensive Research Platform

TORONTO, Nov. 15, 2018 /PRNewswire/ – Strainprint™ Technologies Ltd., the leader in cannabis data and analytics, today announced a partnership with Israeli research leaders, Lumir Lab and Gynica to conduct the world’s first international clinical study on the use of cannabis to treat endometriosis. Endometriosis, a condition where tissue from the uterine lining migrates to other organs inside the body affects roughly 180 million women worldwide. It is estimated that 1 in 10 women between the ages of 15 to 49 will be affected by symptoms of endometriosis during their lifetime.

Strainprint’s VP of Research, Michelle Arbus, will work closely with world-renowned cannabis scientist, Professor Lumir Hanus, along with Gynica’s Professor Moshe Hod, President of the European Association of

... read more at: https://www.prnewswire.com/news-releases/strainprint-technologies-lumir-lab-and-gynica-announce-clinical-trial-partnership-establishing-worlds-first-and-largest-database-of-medical-cannabis-effects-on-women-300751315.html

by

Leave a Reply